Short Interest in bioMerieux (OTCMKTS:BMXMF) Declines By 37.8%

Key Points

• Short interest in bioMerieux decreased significantly by 37.8% in September, dropping from 137,900 shares to 85,800 shares.
• The days-to-cover ratio for bioMerieux is currently at 858.0 days, based on an average trading volume of 100 shares.
• As of the latest data, bioMerieux's stock price opened at $135.01, with a 1-year price range between $100.50 and $152.00.

bioMerieux (OTCMKTS:BMXMF - ) was the recipient of a significant drop in short interest during the month of September. As of September 15th, there was short interest totaling 85,800 shares, a drop of 37.8% from the August 31st total of 137,900 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 858.0 days. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 858.0 days.

bioMerieux Stock Performance

Shares of OTCMKTS BMXMF opened at $135.01 on Friday. bioMerieux has a 1 year low of $100.50 and a 1 year high of $152.00. The firm's 50 day moving average price is $140.96 and its 200 day moving average price is $136.15. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.30 and a current ratio of 2.27.

About bioMerieux

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.